Inscription Capital’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.53M Buy
2,754
+99
+4% +$100K 0.27% 65
2025
Q4
$2.85M Buy
2,655
+874
+49% +$836K 0.29% 52
2025
Q3
$1.36M Buy
1,781
+317
+22% +$236K 0.15% 113
2025
Q2
$1.14M Buy
1,464
+158
+12% +$123K 0.16% 98
2025
Q1
$1.02M Buy
+1,306
New +$1.09M 0.17% 99
2024
Q3
$1.08M Buy
1,222
+12
+1% +$10.8K 0.16% 104
2024
Q2
$1.1M Sell
1,210
-96
-7% -$76.8K 0.18% 92
2024
Q1
$1.02M Buy
1,306
+359
+38% +$255K 0.17% 99
2023
Q4
$552K Buy
947
+93
+11% +$54.3K 0.15% 108
2023
Q3
$459K Sell
854
-27
-3% -$13.9K 0.15% 107
2023
Q2
$413K Buy
881
+7
+0.8% +$2.94K 0.13% 123
2023
Q1
$300K Buy
874
+15
+2% +$5.06K 0.08% 159
2022
Q4
$314K Hold
859
0.11% 153
2022
Q3
$278K Buy
859
+5
+0.6% +$1.58K 0.08% 163
2022
Q2
$277K Hold
854
0.05% 212
2022
Q1
$245K Sell
854
-50
-6% -$12.9K 0.07% 168
2021
Q4
$250K Buy
+904
New +$229K 0.07% 193
2021
Q3
Sell
-3,245
Closed -$745K 318
2021
Q2
$745K Buy
+3,245
New +$652K 0.08% 155

Other funds holding LLY

Inscription Capital's LLY Position: Q1 2026 in Review

Inscription Capital increased its Eli Lilly (LLY) stake by 3.7% in Q1 2026, buying an estimated $100K and bringing the position to 2,754 shares worth $2.53M. The position accounts for 0.27% of the portfolio, ranked #65.

Inscription Capital first reported a position in LLY in Q2 2021 and has held it in 18 quarters since. The position peaked at $2.85M in Q4 2025. 4,354 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Inscription Capital held 2,754 shares of Eli Lilly worth $2.53M as of Q1 2026.
  • Inscription Capital bought 99 Eli Lilly shares in Q1 2026, an estimated $100K.
  • Eli Lilly made up 0.27% of Inscription Capital's portfolio in Q1 2026, its #65 holding.
  • Inscription Capital first reported a position in Eli Lilly in Q2 2021 and has held it in 18 quarters since.
  • Inscription Capital's Eli Lilly position peaked at $2.85M in Q4 2025.
  • 4,354 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Inscription Capital's 13F filing for Q1 2026, filed 20 Apr 2026.